We present a Peruvian human immunodeficiency virus (HIV)-positive patient receiving first-line therapy for tuberculosis who presents with neurological complications to highlight some of the major issues in the diagnosis and management of human immunodeficiency virus-related central nervous system complications in resource-poor settings. These include limited options for diagnosing extrapulmonary and drug-resistant tuberculosis; the importance of central nervous system imaging; and the management conundrum when faced with a broad differential diagnosis. This patient was diagnosed with drug-resistant tuberculosis of the skin, and we felt that his neurologic syndrome was consistent with drug-resistant tuberculosis of the brain, unmasked by immunologic recovery in the setting of recent initiation of antiretroviral treatment. We argue that aggressive and timely empiric multidrug-resistant tuberculosis treatment is important in cases where drug-resistant tuberculosis is suspected. Knowledge gaps include a limited understanding of immune reconstitution and the optimal timing of antiretroviral treatment in the setting of drug-resistant tuberculosis.
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Keywords: HIV; tuberculosis; drug-resistant tuberculosis or MDR-TB; immune reconstitution syndrome (IRS); resource-poor setting Case A 29-year-old man (DM) with human immunodeficiency virus (HIV) and tuberculosis (TB) with left-hand side hemiballismus, and fever. DM was diagnosed with HIV in 2005. His initial CD4 count was 53 cells/mm 3 , and HIV viral load 790 000 copies/mL without prior antiretroviral therapy (ART Figure 1A ) revealed multifocal circumscribed lesions with T2 prolongation, without enhancement or mass effect, involving the left caudate head, left putamen, left medial thalamus, left posterior thalamus, and the junction of the right cerebral peduncle and midbrain.There was no abnormal meningeal enhancement. None of the lesions had a hypointense rim. The patient initiated trimethoprimsulfamethoxazole (T/S) and clindamycin for possible toxoplasmosis as well as dexamethasone (initial dose 4 mg every 6 hours) and improved. About 3 months later, he initiated ART with zidovudine, lamivudine, and efavirenz. About 1 month after ART initiation, DM presented with subacute dysarthria, confusion, and lack of sphincter control. At that time, he was receiving HRE for TB therapy and T/S for secondary toxoplasmosis prophylaxis. Cerebrospinal fluid was nondiagnostic; serum cryptococcal antigen was negative. Precontrast and postcontrast head computed tomography (CT; Figure 1B Figure 1C ). At that time, viral load was <400 copies/mL, and CD4 count was 222 cells/mm 3 .
Discussion
This case from an urban resource-poor setting (Lima, Peru) highlights some of the challenges in diagnosis and management of suspected drug-resistant extrapulmonary TB among HIV-positive individuals. The convergence of drug-resistant TB and HIV poses unique clinical challenges 1-3 ; among these, involvement of the central nervous system (CNS) presents one of the most difficult manifestations, with significant morbidity and mortality. [4] [5] [6] [7] The emergence of HIV and drug-resistant TB as relentless forces in the TB epidemic has accelerated the push for innovative TB diagnostics. [8] [9] [10] [11] The ideal method must diagnose TB from smear-negative specimens, identify resistance to at least INH and RIF, and perform under basic laboratory conditions at minimal cost. In Peru, M tuberculosis polymerase chain reaction (PCR) is costly and difficult to access, and CSF testing for M tuberculosis using conventional microscopy and culture has been of little yield in our experience. For DM, the diagnosis of drugresistant TB was made by MODS assay on tissue obtained from a cutaneous abscess, supporting the strategy of aggressively searching for simultaneous involvement of any sites amenable to biopsy. 12 Were it not for courtesy MODS testing and research in Peru, this method would not have been available. In reality, bacteriologic confirmation of TB and/or drug-resistant TB is rare among HIV-positive individuals with suspected extrapulmonary TB.
For the majority, the presumptive diagnosis of drug-resistant TB is based upon 3 considerations: (1) TB treatment history; (2) clinical and radiographic features; and (3) exclusion of alternative diagnoses. This patient had received suboptimal TB treatment, with a history of nonadherence and default. Furthermore, twice-weekly continuation phase for Category I treatment is associated with an increased risk of relapse and acquisition of RIF resistance among HIV-positive patients. [13] [14] [15] Thus, suboptimal therapy increased our clinical suspicion of drug resistance.
The most challenging aspect in diagnosing such cases is excluding alternative diagnoses. We have had several cases with multiple CNS infections, consistent with other reports. 16 In the absence of definitive diagnosis, our approach has often been to simultaneously treat the most likely causes, a common approach in managing HIV-positive patients in resource-poor settings given the paucity of diagnostic tools. This strategy, while practical, often does not help narrow the diagnosis based on clinical response. Availability of CT and/or MRI has been instrumental. Initial lesions of this case are suggestive of toxoplasmosis except for the absence of contrast enhancement. At the second presentation, the multifocal, bilateral distribution of abnormality involving deep white and gray matter with mass effect and treatment history for both toxoplasmosis and pulmonary TB focus the differential diagnosis on 3 entities: CNS lymphoma partially suppressed by steroids, paradoxical worsening of toxoplasmosis, or an atypical presentation of CNS TB. Although primary CNS lymphoma in patients with AIDS may present without enhancement and the use of high-dose steroids at initial presentation could have suppressed lymphoma producing temporary improvement, the absence of high CT attenuation in the lesions makes this less likely. Combined with the patient's subsequent improvement and survival without specific therapy for CNS lymphoma or continuing steroid use, these features essentially exclude CNS lymphoma. Given the progression of neurologic symptoms, the lack of rim enhancement would be extremely unusual in toxoplasmosis, which typically presents with multiple predominantly periventricular lesions having prominent ring enhancement. Although literature documents CNS toxoplasmosis without enhancement in patients after bone marrow transplantation, to our knowledge HIV-related toxoplasmosis without enhancement has not been previously reported. 17, 18 Central nervous system TB typically presents with meningeal enhancement, irregularly bordered rim enhancement and variable central necrosis and late calcification [19] [20] [21] ; however, a recent carefully controlled observational study demonstrated absence of contrast enhancement in approximately 20% of patients with CNS TB, whether or not treated with steroids. 22 Although successful, the empiric management of this case makes arriving at definitive diagnosis difficult. Clinical improvement could be due to immunologic recovery from ART alone or from MDR-TB treatment. Both toxoplasmosis and CNS TB could have worsened in the setting of ART initiation, or drug-resistant TB could have progressed in the setting of inadequate therapy. Nevertheless, the tissue-proven extrapulmonary drug-resistant TB, absence of contrast enhancement, minimal response to steroids following the second neurologic presentation, and subsequent improvement after starting MDR-TB therapy lead us to argue that DM had CNS involvement of drug-resistant TB.
The most challenging alternative diagnosis is immune reconstitution inflammatory syndrome (IRIS), 23, 24 which generally refers to the paradoxical deterioration or ''unmasking'' of clinical disease associated with a marked inflammatory response in the setting of immunologic recovery. Although most frequently associated with initiation of ART in the preceding 6 months, paradoxical inflammatory reactions shortly after starting TB treatment have been observed in HIV-negative patients as well. 5, [25] [26] [27] Lawn et al 28 draw a helpful distinction between cases in which ART ''unmasks'' subclinical disease and those cases in which antiretrovirals trigger an exaggerated inflammatory syndrome associated with TB. Certainly, postmortem series in HIV-negative and HIV-positive patients demonstrate that subclinical disseminated TB, including CNS involvement, is common. 16, [29] [30] [31] [32] [33] [34] In our case, these alternative diagnoses of drug-resistant TB and IRIS were not necessarily mutually exclusive. The patient developed his second neurological complication shortly after initiating ART. However, he had received 8 months of TB treatment; were it drug-susceptible TB, the TB should have been adequately controlled, if not cured, at the time of starting ART. On the other hand, initiation of highly active antiretroviral therapy (HAART) in the setting of inadequately treated drug-resistant TB may have prompted inflammatory exacerbation and CNS symptoms. We argue that this case demonstrates the role of ART in ''unmasking'' subclinical drug-resistant TB. In sites with high rates of primary MDR-TB among HIV-coinfected individuals and/or use of twice-weekly continuation phase, unfavorable response to TB treatment should raise the suspicion not only of IRIS but also of drugresistant disease. 35 Although some speculate that deferring ART could decrease mortality by avoiding fatal IRIS, 36 we feel that, on the contrary, the mortality associated with undiagnosed and untreated TB likely outweighs the potential pitfall of ''unmasking'' drug-resistant TB. 23 In fact, in settings with significant rates of drug-resistant TB, early initiation of ART may be all the more important to accelerate timely diagnosis of drug-resistant cases and increase chances of cure by improving immunologic function.
Peru is one such region where MDR-TB may account for up to 40% of all cases of HIV/TB coinfection. 35, 37 Management of suspected drug-resistant TB should therefore be aggressive. Implementation of methods to diagnose TB and drug resistance, including use of liquid media-based detection with MODS, BACTEC, or mycobacteria growth indicator tube (MGIT), would likely be clinically effective and cost-effective in resource-poor settings, in particular for HIV-positive patients. 17, 18 To avoid excessive mortality, empiric MDR-TB treatment should be started in suspected cases of MDR-TB HIV coinfection, because bacteriologic confirmation can rarely be obtained and starting steroids in the absence of MDR-TB treatment could be devastating. In April 2004, the Peruvian National TB Program instituted aggressive empiric MDR-TB treatment (which DM received) for Category I and Category II treatment failures. The endorsement of this strong regimen was based on available regional drug resistance data and prior suboptimal experience with less aggressive empiric regimens. 19 This regimen is given while awaiting DST data; if results are obtained, the regimen is individualized according to the patient's resistance pattern. This strategy has achieved excellent outcomes of 70% cure. Given that Category II therapy is associated with worse outcomes in such cases, 22, 38 empiric MDR-TB treatment should have been chosen over Category II treatment for all previously treated HIV/TB coinfected patients, in particular in settings where MDR-TB incidence is high. In addition to regimen choice, delays in initiation of empiric therapy must be addressed: the time from soliciting approval from the MDR-TB treatment committee to initiation of empiric MDR-TB treatment is 1 month or longer. 20, 21 Currently, mechanisms are being elaborated to expedite rapid initiation of MDR-TB treatment in clinically ill cases. For cases with suspected drugresistant TB, in particular with HIV coinfection, an empiric trial of MDR-TB therapy is indicated. In many resource-poor settings, gauging clinical response may be the only way of arriving at a diagnosis, short of autopsy.
Conclusion
The diagnosis and treatment of drug-resistant TB and HIV coinfection poses an important challenge. Central nervous system TB should be considered in the differential diagnosis of brain lesions with edema seen on CT, even in the absence of contrast enhancement. In areas with significant rates of drug-resistance, ''unmasking'' of drug-resistant disease should be strongly considered when patients fail to respond to first-line TB therapy. Aggressive and timely empiric MDR-TB management is essential, even in the absence of bacteriological confirmation of TB or drug-resistance. All possibilities for obtaining a clinical sample for culture and drug sensitivity test (DST) should be explored, and universal drug susceptibility testing using a sensitive and rapid method should be performed on all HIV-positive patients starting treatment. If clinical and/or radiographic suspicion is high, empiric MDR-TB treatment should be initiated given the high mortality associated with treatment delay in this population. We hope that forthcoming developments in diagnostics, greater understanding of immune reconstitution and trials to identify the optimal timing of ART, for TB cases in general and specifically for MDR-TB cases, will reduce the gaps in treatment outcomes observed across gradients of disparity. 39 
